Good and rapid answers.
But I'm not convinced that Tom answered this.
Our orphan drug designations prevent AZ or any pharma from actively marketing Exenatide for IIH.
But what prevents a doctor from prescribing Byetta or Bydureon off-label for IIH? Doctors prescribe off-label all the time.
Is it just the fact that those drugs cost USD 500 per month and insurance won't pay for off-label use? So the only patients who would ask for Byetta and Bydureon are uninsured patients?
Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-53
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.260M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37349 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 14/01/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable
